• AG-490: JAK2/STAT6 Assay Strategy

  2026-09-19

  AG-490, also known as Tyrphostin B42, is a multi-kinase probe for dissecting JAK2-, EGFR-, and STAT-linked biology. This article translates recent exosomal SNORD52–JAK2/STAT6 findings into a rigorous assay strategy while defining the controls needed for cancer research and macrophage-polarization studies.

• Metformin Hydrochloride in Whole-Blood Research

  2026-09-18

  Use Metformin Hydrochloride as a tunable metabolic intervention in standardized whole-blood stimulation, linking AMPK biology with cytokine profiling. This workflow complements hepatocyte and disease-model studies while preserving donor-specific immune and plasma context.

• Toremifene Citrate: Breast Cancer Research Workflow

  2026-09-18

  Toremifene Citrate enables controlled interrogation of estrogen receptor signaling, from receptor-proximal binding assays to delayed antiproliferative responses in breast cancer models. This workflow combines concentration-response design, vehicle control, receptor-context validation, and translational interpretation for more reproducible hormone receptor modulation studies.

• Machine Learning Discovery of Senolytics: Study Analysis

  2026-09-17

  The reference study shows that machine-learning models trained only on published screening data can identify senolytic candidates despite limited and heterogeneous datasets. Computational screening followed by human-cell validation identified ginkgetin, periplocin, and oleandrin, offering a cost-efficient framework for early-stage senolytic discovery.

• Exosomal SNORD52 Activates JAK2/STAT6 in HCC

  2026-09-17

  This study identifies hepatoma cell-derived exosomal SNORD52 as a mediator of M2 macrophage polarization in hepatocellular carcinoma through functional engagement of the JAK2/STAT6 pathway. Its exosome-transfer model connects a non-coding RNA cargo with tumor-associated immune remodeling and provides a framework for testing pathway-directed interventions.

• BMS 599626 dihydrochloride: EGFR/HER2 Workflows

  2026-09-16

  Build reproducible EGFR/HER2 pathway experiments with a dual-receptor inhibitor designed for phospho-signaling, proliferation, and receptor-crosstalk studies. The workflow also shows how to test pathway dependence in breast and lung cancer models without mistaking cytostasis for senolysis.

• Afatinib in Gastric Cancer Assembloid Research

  2026-09-16

  Afatinib, also known as BIBW 2992, offers translational researchers a mechanistically distinctive way to interrogate ErbB-family signaling in patient-derived gastric cancer assembloids. By combining irreversible EGFR, HER2, and HER4 inhibition with matched tumor–stroma models, researchers can separate tumor-intrinsic sensitivity from microenvironment-mediated resistance.

• Estradiol and the Receptor–Autophagy Frontier

  2026-09-15

  A translational perspective on 17 beta-estradiol, estrogen receptor signaling, and autophagy as a systems-level framework for studying cardiovascular, renal, metabolic, and endocrine biology.

• Dacomitinib: From ErbB Signaling to Ferroptosis

  2026-09-15

  Dacomitinib (PF-00299804) offers a precise way to interrogate ErbB-dependent survival signaling while designing deeper ferroptosis assays. This article connects pan-HER pharmacology with METTL17-regulated mitochondrial biology and defines the experiments needed to distinguish apoptosis from ferroptosis.

• Chloramphenicol: Mechanism and Plasmid Selection

  2026-09-14

  Chloramphenicol is a bacterial protein synthesis inhibitor that binds the 50S ribosomal subunit and blocks translation. The A2512 research reagent supports plasmid selection assays, with product-reported working concentrations of approximately 25 μg/mL for stringent plasmids and 170 μg/mL for relaxed plasmids.

• DNase I (RNase-free) for Clean Cancer RNA Workflows

  2026-09-14

  DNase I (RNase-free) supports cleaner RNA extraction, RT-PCR, and in vitro transcription sample preparation when genomic DNA could distort interpretation. This guide connects cation-aware nuclease use with the CCR7–Notch1 cancer-stemness findings and provides practical controls, starting conditions, and troubleshooting steps.

• Lapatinib (GW572016) Assay Workflow Guide

  2026-09-13

  Build receptor-defined kinase assays and phenotype-first oncology workflows around Lapatinib, from EGFR/HER2 phosphorylation to proliferation, invasion, and angiogenesis readouts. The approach also shows how to interpret activity in HER2-negative models without confusing downstream phenotype with confirmed target engagement.

• Tunicamycin as a Causal ER Stress Probe

  2026-09-12

  Tunicamycin is more than an N-glycosylation inhibitor: it is a controlled perturbation for connecting ER proteostasis with inflammatory and HMGB1-centered disease biology. This article translates the QRICH1–ER stress study into practical assay decisions while distinguishing tunicamycin-driven stress from virus-specific mechanisms.

• Estradiol Workflows for ER–Autophagy Research

  2026-09-11

  Build reproducible 17 beta-estradiol experiments that connect receptor activation with autophagy, fibrosis, and multi-organ protection. This guide combines cell-based dose finding, receptor-specific validation, and translational heart, aorta, and kidney workflows with practical troubleshooting.

• Toremifene Citrate Workflows for ER Research

  2026-09-11

  Build reproducible estrogen receptor binding, MCF-7 proliferation, signaling, and rodent tumor workflows with Toremifene Citrate. This guide connects receptor-level potency with practical dosing, solvent control, comparator design, and troubleshooting for translational breast cancer research.

7712 records 1/515 page Next 12345 下5页 Last page